Imagenebio vs Longeveron
Longeveron is the larger business, with $1.2m of revenue in fiscal 2025 against $800,000 for Imagenebio (1.5 times as much). Longeveron grew faster (-49.9% against -77.1%). Longeveron kept more of each dollar of sales as profit: a net margin of -1893.6% against -5668.6%. Imagenebio carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | ImagenebioIMA, 2025 | LongeveronLGVN, 2025 |
|---|---|---|
| Revenue | $800,000 | $1.2m |
| Revenue growth | -77.1% | -49.9% |
| Net income | −$45.3m | −$22.7m |
| Operating margin | -6056.4% | -1942.2% |
| Net margin | -5668.6% | -1893.6% |
| Return on equity | — | -164.7% |
| Free cash flow | −$47.8m | −$18.9m |
| Cash | $94.5m | $4.7m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 15 | 37 |
| Market value | $66.1m | $55.5m |
| Price vs our value range | — | — |
| Moat score | — | 19 (Weak) |
| Insider trades, 12 months | 1 buys, 2 sales | 0 buys, 0 sales |